Related Experiment Video
Updated: May 18, 2026
07:47
Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
Cancer-testis antigen expression and immunogenicity in AL amyloidosis
M A Rosenzweig1, H Landau, D Seldin
1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Cancer Center, Duarte, CA, USA.
Blood Cancer Journal
|September 18, 2012
Summary
Cancer-testis antigens (CTAs) like CT7 are prevalent in light-chain amyloidosis (AL) plasma cells. While CT7 expression is common, spontaneous immunity is rare, suggesting potential for immunotherapy in AL amyloidosis.
Area of Science:
- Immunology
- Oncology
- Hematology
Background:
- Light-chain amyloidosis (AL) is a plasma cell disorder linked to multiple myeloma.
- Cancer-testis antigens (CTAs) are expressed in multiple myeloma, but their role in AL amyloidosis is unclear.
Purpose of the Study:
- To investigate the expression and immunogenicity of CTAs in AL amyloidosis.
- To determine if CTAs can be potential immunotherapy targets in AL amyloidosis.
Main Methods:
- Immunohistochemistry was used on 38 bone marrow specimens from AL amyloidosis patients.
- ELISA was performed on plasma samples from 35 patients to assess seroreactivity to CTA proteins.
Main Results:
- CT7 was expressed in 66% of AL amyloidosis cases, with focal patterns.
- CT10 and GAGE showed lower expression rates (3/38 and 1/38, respectively).
- No spontaneous humoral immunity to CT7 was detected, though some patients showed reactivity to other CTAs.
Conclusions:
- CT7 is the predominant CTA in AL amyloidosis plasma cells.
- CTA expression did not correlate with organ involvement, treatment response, or prognosis.
- CTAs warrant further investigation as potential immunotherapy targets in AL amyloidosis.
